Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akcea Therapeutics Inc.

Division of Ionis Pharmaceuticals Inc.
www.akceatx.com

Latest From Akcea Therapeutics Inc.

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.

Financing Business Strategies

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.

Deals M & A

Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team

Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Metabolic Disorders
  • Alias(es)
  • 1662524
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Paula Soteropoulos, Pres. & CEO
    Michael MacLean, CFO
    Jeffrey M Goldberg , COO
    Molly Harper, VP, Global Commercial Dev.
    Louis St. L O’Dea, MD, CMO
    Mustafa Noor, MD, Chief Dev. Officer
  • Contact Info
  • Akcea Therapeutics Inc.
    Phone: (617) 207-0202
    55 Cambridge Parkway
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register